An interventional study of Titanium-Prepared Platelet-Rich Fibrin (T-PRF) with VISTA Technique and Connective Tissue Graft (CTG) with VISTA Technique in Gingival Diseases and Gingival Recession, sponsored by Arab International University. Completed at 1 site in Syria. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Arab International University · Not applicable, Interventional, and Treatment
This split-mouth randomized clinical trial aims to compare the effectiveness of titanium-prepared platelet-rich fibrin (T-PRF) and connective tissue graft (CTG) in the treatment of Miller Class I and II gingival recession using the Vertical Incision Subperiosteal Tunnel Access (VISTA) technique. Twenty systemically healthy adult participants with bilateral gingival recession defects will receive both interventions, with one side randomly assigned to T-PRF and the contralateral side assigned to CTG. Clinical outcomes including recession depth, attached gingival width, probing depth, relative attachment level, healing, and patient satisfaction will be evaluated over a 6-month follow-up period.
Gingival recession is a common periodontal condition characterized by apical displacement of the gingival margin, resulting in root exposure, dentin hypersensitivity, esthetic concerns, and increased susceptibility to root caries. Connective tissue grafts (CTG) are widely considered the gold standard for root coverage procedures due to their predictable clinical outcomes. However, CTG requires harvesting tissue from a secondary surgical donor site, which may increase postoperative discomfort and patient morbidity.
Titanium-prepared platelet-rich fibrin (T-PRF) is a second-generation autologous platelet concentrate prepared using titanium tubes, which may enhance fibrin network quality and improve soft tissue healing and regeneration. T-PRF has been proposed as a less invasive alternative to CTG in periodontal plastic surgery.
The present study is designed as a split-mouth randomized controlled clinical trial to compare T-PRF and CTG in the treatment of bilateral Miller Class I and II gingival recession defects using the Vertical Incision Subperiosteal Tunnel Access (VISTA) technique. Twenty systemically healthy adult participants with symmetrical gingival recession defects will be enrolled. Each participant will receive both interventions: one side of the mouth will be randomly assigned to treatment with VISTA combined with CTG, while the contralateral side will receive VISTA combined with T-PRF.
Randomization will be performed using a computer-generated allocation sequence prepared by an independent investigator. Due to the nature of the interventions, operator blinding is not feasible; however, all clinical measurements and outcome assessments will be conducted by a blinded examiner.
Clinical parameters including gingival recession depth, attached gingival width, probing depth, and relative attachment level will be measured at baseline, 3 months, and 6 months postoperatively using a UNC-15 periodontal probe. Early wound healing will be assessed at 1, 2, and 4 weeks using a healing index. Patient-reported satisfaction and postoperative outcomes will be evaluated using a visual analog scale (VAS).
The study aims to determine whether T-PRF can provide comparable clinical and patient-centered outcomes to CTG while reducing the morbidity associated with donor site harvesting.
426 studies on the registry are indexed under Gingival Recession; 106 are open to participants now.
This study's enrollment of 20 is below the median of 30 across 390 interventional studies indexed under Gingival Recession.
Browse Gingival Recession studies →Arab International University is the lead sponsor of 5 studies on the registry; none are open to participants now.
Compared within Gingival Recession, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Gingival Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Sites allocated to the test group will be treated using the Vertical Incision Subperiosteal Tunnel Access (VISTA) technique in combination with titanium-prepared platelet-rich fibrin (T-PRF). T-PRF membranes will be prepared from autologous venous blood collected in titanium tubes and centrifuged according to a standardized protocol before placement beneath the tunneled gingival tissue.
Procedure: Titanium-Prepared Platelet-Rich Fibrin (T-PRF) with VISTA Technique
Sites allocated to the control group will be treated using the Vertical Incision Subperiosteal Tunnel Access (VISTA) technique in combination with an autogenous connective tissue graft (CTG) harvested from the palatal donor site and placed beneath the tunneled gingival tissue for root coverage.
Procedure: Connective Tissue Graft (CTG) with VISTA Technique
The gingival recession defects assigned to the test group will be treated using the Vertical Incision Subperiosteal Tunnel Access (VISTA) technique combined with titanium-prepared platelet-rich fibrin (T-PRF). T-PRF membranes will be prepared from the participant's autologous venous blood collected in titanium tubes and centrifuged according to a standardized protocol before placement beneath the tunneled flap.
The gingival recession defects assigned to the control group will be treated using the Vertical Incision Subperiosteal Tunnel Access (VISTA) technique combined with an autogenous connective tissue graft (CTG). The graft will be harvested from the palatal donor site and positioned beneath the tunneled gingival tissue to achieve root coverage and soft tissue augmentation.
Gingival Recession Depth
Change in gingival recession depth measured in millimeters (mm) from the cementoenamel junction to the free gingival margin using a UNC-15 periodontal probe. Lower values indicate better root coverage outcomes.
Time frame: Baseline, 3 months, and 6 months postoperatively.
Width of Attached Gingiva
Change in the width of attached gingiva measured in millimeters (mm) using a UNC-15 periodontal probe. Higher values indicate improved gingival tissue augmentation and periodontal stability.
Time frame: Baseline, 3 months, and 6 months postoperatively.
Periodontal Probing Depth
Change in periodontal probing depth measured in millimeters (mm) using a UNC-15 periodontal probe at treated sites. Lower values indicate better periodontal health.
Time frame: Baseline, 3 months, and 6 months postoperatively.
Relative Clinical Attachment Level
Change in relative clinical attachment level measured in millimeters (mm) using a UNC-15 periodontal probe. Lower values indicate improved periodontal attachment.
Time frame: Baseline, 3 months, and 6 months postoperatively.
Early Wound Healing Index
Early wound healing assessed clinically using the Early Healing Index (EHI). The scale ranges from 1 to 5, where: 1 = Complete flap closure without fibrin line (best healing) 5 = Incomplete flap closure with complete tissue necrosis (worst healing) Lower scores indicate better healing outcomes.
Time frame: 1 week, 2 weeks, and 4 weeks postoperatively.
Patient Satisfaction
Patient satisfaction assessed using a Visual Analog Scale (VAS). The scale ranges from 0 to 10, where: 0 = Completely dissatisfied 10 = Completely satisfied Higher scores indicate greater patient satisfaction with the treatment outcome.
Time frame: 3 months and 6 months postoperatively.
Postoperative Pain
Postoperative pain assessed using a Visual Analog Scale (VAS). The scale ranges from 0 to 10, where: 0 = No pain 10 = Worst imaginable pain Lower scores indicate less postoperative pain and discomfort.
Time frame: 1 week and 2 weeks postoperatively.
Plan to share: No
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Arab International University